Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206347 | 0.88 | FFAR1 (0.47) | ALDH1A1LMNA | |
| SCHEMBL26206075 | 0.84 | ADRB2 (0.37) | ADRB2ADRB1 | |
| SCHEMBL26205928 | 0.81 | ADRB2 (0.44) | ADRB2ADRB1 | |
| SCHEMBL26206137 | 0.80 | EPHX2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL22526666 | 0.80 | ADRB2 (0.37) | ADRB2ADRB1 | |
| SCHEMBL26206322 | 0.74 | MAPT (0.43) | — | |
| SCHEMBL22527188 | 0.73 | LMNA (0.35) | ALDH1A1LMNA | |
| SCHEMBL22922181 | 0.72 | CYP4F2 (0.59) | ADRB2ADRB1HRH3ALDH1A1LMNA | |
| SCHEMBL23599298 | 0.71 | CYP4F2 (0.56) | ADRB2ADRB1ALDH1A1LMNAIDO1 | |
| SCHEMBL22526938 | 0.69 | ATM (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | ADRB2 4571/4885ADRB1 4560/4885HRH3 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.